Work

Successful treatment of Anti-NF155 antibody positive autoimmune nodopathy with telitacicept: a case report

Year: 2026

Type: article

Abstract: Autoimmune Nodopathy (AN) has been classified as an independent disease due to significant differences in pathological features and clinical manifestations from chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), yet it is often overlooked or misdiagnosed. We report a case of neurofascin-155 (NF155) + AN in a 76-year-old male. Innovatively, we introduced the dual B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) inhibitor telitacicept as first-line therapy immediately after diagnosis. This therapeutic approach led to rapid and sustained disease control in the patient. Beyond demonstrating the critical importance of early diagnosis and targeted therapy in preventing irreversible neurological damage, this case provides compelling preliminary evidence for the favorable efficacy and safety of telitacicept, supporting its potential as a first-line treatment for AN, particularly in the NF155 + subtype.

Source: BMC Neurology

DOI: 10.1186/s12883-026-04841-5

Authors: Zhuqing Luan, Minghui Du, Zhigang Liang, Fuxia Song

Institutions: Qingdao University, Yuhuangding Hospital

Language: English

Topic: Peripheral Neuropathies and Disorders

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,090